RxDoctor Payments Data

Denis Wadzani

Family · Culver City, CANPI 1386177129

Payments from drug & device makers

$789in general payments, 2019–2025

Across 33 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$125
  • Novartis$114
  • Teva Pharmaceuticals USA, Inc.$99
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$87
  • Astellas Pharma US Inc$67
  • Hologic Sales And Service, LLC$48
  • plus $249 from 9 others

What the payments were for

  • Food & beverage$789100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$789 in reported general payments places this provider in the 70th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$15,720
Medicare patients
68
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Metformin Er GastricMetformin Hcl106$153,571
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate89$31,510
EliquisApixaban50$31,440
OzempicSemaglutide26$24,769
LinzessLinaclotide42$23,712
Diclofenac Sodium29$16,180
FycompaPerampanel12$15,584
JardianceEmpagliflozin27$15,205
MyrbetriqMirabegron31$14,509
Metformin Er OsmoticMetformin Hcl30$13,056
JanuviaSitagliptin Phosphate18$10,823
Atorvastatin Calcium757$8,858
XareltoRivaroxaban12$7,456
Breo ElliptaFluticasone/Vilanterol13$5,543
Midodrine Hcl75$5,307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$22$23,71242 claims
Astellas Pharma US IncMyrbetriq$67$14,50931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,634 family providers in California.

Other family in Culver City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →